Navigation Links
Vaginal Microbicides Might Help More Men Than Women
Date:7/10/2008

Researchers say clinical trials' design may also mask risk of HIV drug resistance

THURSDAY, July 10 ( HealthDay News) -- A new study questions whether vaginal microbicides being developed to help protect women against HIV infection could lead to new drug resistance from the virus that causes AIDS.

The study, published July 7 in the online issue of Proceedings of the National Academy of Sciences, also shows that, under certain circumstances, men may actually benefit a bit more than women from the microbicides, which are compounds that can be applied inside the vagina.

Drug companies are running clinical trials on some second-generation microbicides based on antiretroviral, or ARV, medicines.

The study by the UCLA AIDS Institute also questions the designs of these trials. The researchers made the conclusions by using mathematical models that simulate clinical trials and population-level transmission of HIV.

Under the scenarios the researchers developed, men were slightly more protected than woman in certain situations. This occurred when the in-trial microbicide, an ARV drug called dapivirine, was only effective about half the time in women -- a situation that could occur if HIV-positive women on microbicides developed drug-resistant strains of HIV that were then less likely to be transmitted to men.

"The antiretroviral drugs within these microbicides are the same as those used to treat people who are infected with HIV, so there is great expectation that these microbicides will be very effective," said first author Dr. David Wilson, of the National Centre in HIV Epidemiology and Clinical Research at Australia's University of New South Wales, in a prepared statement.

"But the concern is that these microbicides are going to lead to drug resistance," he said.

Concerns about drug resistance come from the fact that the current clinical trial drops women from the study if they turn up HIV-positive during monthly screening, the researchers said.

"Since monthly testing will take place in the dapivirine trial, we predict that few, if any, cases of acquired resistance will arise during the trial, even if the drug is readily absorbed (i.e., the microbicide is high risk)," the researchers wrote. "Therefore, our analyses have shown that high-risk microbicides could pass Phase III trials, as their potential to cause resistance will be masked by frequent testing."

More information

The U.S. Department of Health & Human Services has more about HIV prevention drugs.



-- Kevin McKeever



SOURCE: University of California, Los Angeles, news release, July 7, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. HIV prevention researchers to compare common ARV as a pill and vaginal gel in unique study
2. Study Finds More Than One in Two Women are Too Embarrassed to Discuss Vaginal Discomfort With Their Doctors
3. IPM Reaches Landmark Agreement with Pfizer to Develop FDA-Approved Antiretroviral Drug as Vaginal Microbicide
4. Antiretroviral Drugs May Prevent Vaginal Transmission of HIV
5. Vaginal progesterone gel may improve infant outcomes and...
6. Researchers develop new tool to predict who will use microbicides
7. ADHD Might Raise Kids Obesity Risk
8. Meditation, Yoga Might Switch Off Stress Genes
9. Could new discovery about a shape-shifting protein lead to a mighty morpheein bacteria fighter?
10. Stem Cells Might Treat Tough Fractures
11. Diabetes Might Help Spur Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Vaginal Microbicides Might Help More Men Than Women
(Date:6/25/2016)... Viejo, California (PRWEB) , ... June 25, 2016 , ... ... to fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... fully customizable and all within Final Cut Pro X . Simply select a ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, ... at Work award to iHire in recognition of their exemplary accomplishments in worksite health ... annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World ... with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
(Date:6/24/2016)... 24, 2016 Research and Markets has ... Companion Diagnostic Tests" report to their offering. ... Diagnostics The World Market for Companion Diagnostics ... diagnostics. Market analysis in the report includes the following: ... Vitro Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
Breaking Medicine Technology: